Advaxis, Inc. Receives Notice Of Allowance From U.S. Patent And Trademark Office For Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
4/1/2014 9:25:39 AM
PRINCETON, N.J., April 1, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension.
Help employers find you! Check out all the jobs and post your resume.
comments powered by